Fulgent Genetics Awarded Contract By The U.S. Department Of Veterans Affairs To Provide Hereditary Cancer, Pharmacogenetic And Other Genetic Testing To Veterans; The Award Is For Up To $99M Over 5-Years, Including Both Hereditary Cancer Testing And Pharmacogenetic Testing
Portfolio Pulse from Benzinga Newsdesk
Fulgent Genetics has been awarded a five-year contract worth up to $99 million by the U.S. Department of Veterans Affairs to provide genetic testing services, including hereditary cancer and pharmacogenetic testing, to veterans.
October 31, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fulgent Genetics has secured a significant contract with the U.S. Department of Veterans Affairs, potentially boosting its revenue and market position in genetic testing services.
The contract with the VA is substantial, valued at up to $99 million over five years, which is likely to positively impact Fulgent's revenue. The deal also strengthens Fulgent's position in the genetic testing market, particularly in serving veterans, a significant and stable client base.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100